UMMC Navigation

Available Trials

Lymphoma

For more information regarding these studies, contact Cancer Research & Registry at (601) 984-1095

ASN002-101: A Phase 1/2, Open-Label, Uncontrolled, Multidose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors

This study is for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), Follicular Lymphoma (FL), Mantel Cell Lymphoma (MCL) or Advanced Solid Tumors (Part A only). The purpose of this study is to find the safest dose of ASN002, and to see if it has any effects against certain cancers.

Cancer cells can cause uncontrollable cell growth. Studies have shown that blocking certain enzymes called Spleen Tyrosine kinase (SYK) and Janus kinase (JAK) can slow or stop cancer growth.

Principal Investigator: Stephanie Elkins, MD